John O'Neill, a pharmaceutical industry analyst at visiongain, said: "Entry of more-efficacious treatments to the MS drug market - and drugs that can be taken orally rather than injected - will expand the treated patient population. There is scope for important developments in national markets such as the UK, where the number of MS patients is high and treatment can be improved."
In particular, this new study predicts the future of the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya, showing revenue forecasts to 2022. The report discusses companies such as Biogen Idec, Teva, Sanofi, Novartis, Merck Serono and Bayer. It also assesses the R&D pipeline for treating multiple sclerosis and forecasts leading national markets.
With a strong R&D pipeline, the MS treatment market will expand this decade. Products from its pipeline will help patients, as will extensions of the indication ranges for marketed drugs. Multiple Sclerosis Treatment: World Drug Market 2012-2022 adds to visiongain's range of analytical research reports on immune disorders, neurodegenerative disorders and other therapeutic areas.
To see report sample pages please visit http://www.visiongain.com/
Please contact Sara Peerun for an exec summary:
Tel: +44 020 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@
# # #
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.